Developmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukaemia
Giles, Francis Mahon, François-Xavier Gjertsen, Bjorn Swords, Ronan Labar, Boris Turkina, Anna Rosti, Gianantonio
Giles, Francis
Mahon, François-Xavier
Gjertsen, Bjorn
Swords, Ronan
Labar, Boris
Turkina, Anna
Rosti, Gianantonio
Publication Date
2012-05-01
Keywords
chronic myeloid leukaemia, dasatinib, developmental therapeutics consortium, imatinib, nilotinib, tyrosine kinase inhibitors, early chronic-phase, chronic myelogenous leukemia, bcr-abl mutations, diagnosed chronic-phase, up sustained survival, follow-up, kinase domain, cml-cp, european-leukemianet, selective inhibitor
Type
journal article
Downloads
Citation
Giles, Francis; Mahon, François-Xavier; Gjertsen, Bjorn; Swords, Ronan; Labar, Boris; Turkina, Anna; Rosti, Gianantonio (2012). Developmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation 42 (9), 1016-1026
Abstract
Eur J Clin Invest 2012; 42 (9): 10161026 Abstract Background Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukaemia (CML). Results from ongoing phase 3 trials with nilotinib [Efficacy and Safety in Clinical TrialsNewly Diagnosed Patients (ENESTnd)] and dasatinib [Dasatinib Versus Imatinib Study in Treatment-Naive CML-CP Patients (DASISION)] in newly diagnosed patients with CML in chronic phase have demonstrated that these TKIs resulted in significant improvements in responses vs. imatinib. Design The Developmental Therapeutics Consortium (DTC) systematically reviewed the published literature to provide a comparative analysis of the ENESTnd and DASISION trial designs and data reported on each study. Results The recent approval of nilotinib and dasatinib based on these two pivotal studies offers physicians the option to optimise frontline treatment based on a patients comorbidities, risk factors and tolerability profiles. Although nilotinib and dasatinib provide effective therapeutic options for the frontline treatment of CML, the lack of an evidenced-based, side-by-side comparison makes it difficult to directly compare these agents. Conclusions Despite potential bias from differences in patient populations and study design, indirect cross-trial comparisons to determine the relative effectiveness of these agents will be performed by physicians. This DTC report provides a comprehensive summary of the study designs, protocols and results of the ENESTnd and DASISION trials, which will assist physicians in making informed decisions on the best treatment approach for their patients.
Funder
Publisher
Wiley-Blackwell